Keyphrases
Hazard Ratio
100%
Carfilzomib
100%
Candour
100%
Daratumumab
100%
Confidence Interval
60%
Multiple Myeloma
40%
Odds Ratio
40%
Progression-free Survival
40%
Minimal Residual
40%
Clinically Significant
20%
Subgroup Analysis
20%
Standard of Care
20%
Protease Inhibitors
20%
Overall Survival
20%
Survival Benefit
20%
Patient Subgroups
20%
Open-label Trial
20%
Median Overall Survival
20%
Median Progression-free Survival
20%
Overall Survival Benefit
20%
Safety Signal
20%
Lenalidomide
20%
Point Analysis
20%
Complete Response Rate
20%
Achievement Rate
20%
High-risk Cytogenetics
20%
Medicine and Dentistry
Hazard Ratio
100%
Dexamethasone
100%
Carfilzomib
100%
Daratumumab
100%
Overall Survival
60%
Progression Free Survival
60%
Multiple Myeloma
40%
Odds Ratio
40%
Subgroup Analysis
20%
Proteasome Inhibitor
20%
Lenalidomide
20%
Open-Label Trial
20%
Pharmacology, Toxicology and Pharmaceutical Science
Dexamethasone
100%
Carfilzomib
100%
Daratumumab
100%
Overall Survival
75%
Progression Free Survival
75%
Multiple Myeloma
50%
Proteasome Inhibitor
25%
Lenalidomide
25%
Open-Label Trial
25%
Immunology and Microbiology
Dexamethasone
100%
Daratumumab
100%
Progression Free Survival
75%
Overall Survival
75%
Multiple Myeloma
50%
Proteasome
25%
Lenalidomide
25%
Agricultural and Biological Sciences
Dexamethasone
100%
Confidence Interval
75%
Odds Ratio
50%
Cytogenetics
25%
Proteasome
25%